HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1760854NBTX stock profile & AI dashboard →
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

28.4/100

Rank #2,556 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

NBTX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Nanobiotix S.A. (NBTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NBTX at 28.4/100 on a 32-signal composite quality model, placing it at rank #2,556 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of NBTX by reported 13-F value include JOHNSON & JOHNSON, MORGAN STANLEY, JANE STREET GROUP, based on the most recent SEC filings. NBTX trades on the Nasdaq exchange and files with the SEC under CIK 1760854. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nanobiotix S.A. directly from SEC EDGAR. Nanobiotix S.A.'s 13F Pro composite quality score has ranged between 28 and 29 since 2026, currently 28.4 — a stable long-term trajectory across 18 quarterly and live scoring snapshots.

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+553.2% YoY
$32.6MFY 2025
FY22 $4.8MFY23 $36.2MFY24 $-7.2MFY25 $32.6M

Total Assets

+0.5% YoY
$67.8MFY 2025
FY22 $59.8MFY23 $93.9MFY24 $67.4MFY25 $67.8M

Get alerted when NBTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Nanobiotix S.A. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of NBTX

Companies Similar to NBTX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CVRX

CVRx, Inc.

24
AI score
Very similar · 1 shared holders
XNCR

Xencor Inc

13
AI score
Shared smart-money ownership · 1 shared holders
FATE

FATE THERAPEUTICS INC

6
AI score
Shared smart-money ownership · 1 shared holders
LEGN

Legend Biotech Corp

50
AI score
Similar quality profile · 1 shared holders
INCR

Intercure Ltd.

29
AI score
Similar quality profile
TRIB

TRINITY BIOTECH PLC

27
AI score
Similar quality profile
CLLS

Cellectis S.A.

27
AI score
Similar quality profile
MTEX

MANNATECH INC

26
AI score
Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put NBTX on your watchlist

Track score changes the day Nanobiotix S.A. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NBTX a good stock to buy?

13F Pro's AI-powered analysis of Nanobiotix S.A. (NBTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NBTX are available on the NBTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NBTX is classified as a small company.

Which hedge funds own NBTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NBTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nanobiotix S.A.'s investment landscape.